Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site

Oragenics Inc. (NYSE American: OGEN) has announced active enrollment at a second clinical site in its Phase IIa trial evaluating ONP-002 for the treatment of concussion and mild traumatic brain injury. The company has already dosed four patients at its initial site in Australia, marking progress toward a planned data readout by year-end 2026.

The advancement underscores Oragenics’ focus on addressing significant unmet medical needs in neurological care. ONP-002 is being developed as a potential first-in-class treatment for concussion, a condition that affects millions of people worldwide each year. The company’s proprietary intranasal delivery technology is designed to target the brain directly, offering a novel approach to treating neurological conditions.

According to the announcement, the Phase IIa trial is evaluating the safety and efficacy of ONP-002 in patients with concussion and mild traumatic brain injury. The expansion to a second site is expected to accelerate patient enrollment and data collection. Following the completion of the Phase IIa trial, Oragenics plans to initiate U.S. Phase 2b trials.

The company’s intranasal delivery platform has broader potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, post-traumatic stress disorder (PTSD), and anxiety disorders. This platform could enable the development of therapies that bypass the blood-brain barrier, a major challenge in treating brain disorders.

Oragenics is a clinical-stage biotechnology company dedicated to developing innovative therapies for neurological conditions. The company’s lead candidate, ONP-002, represents a potential breakthrough in concussion treatment, where current options are limited to symptom management and rest.

Investors and stakeholders can find the latest news and updates about Oragenics at the company’s newsroom at https://ibn.fm/OGEN. For more information about Oragenics and its pipeline, visit oragenics.com.

The announcement was made through BioMedWire, a specialized communications platform focused on the biotechnology and life sciences sectors. The full press release can be accessed at https://ibn.fm/SA2Fu.

Oragenics’ progress in the Phase IIa trial is a critical step forward in the development of a much-needed treatment for concussion. With the expansion to a second site and the planned data readout in 2026, the company is moving closer to potentially offering a new therapeutic option for patients suffering from mild traumatic brain injury.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site.

The post Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site appeared first on citybuzz.